Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Taletrectinib & Non-Small-Cell Lung Carcinoma (NSCLC) (ROS1 +)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

On June 11, 2025, the Food and Drug Administration approved taletrectinib for adults with locally advanced or metastatic Non-small-cell lung cancer (NSCLC) (ROS1 +)
AACR FDA Approval Alert 06/11/25

Taletrectinib for the treatment of ROS-1 positive non-small cell lung cancer: a drug evaluation of phase I and II data
Nagasaka et al. 2024 Expert Opinion on Investigational Drugs 33(2): 79-84
Review

7/1/2026